<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="64">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160311</url>
  </required_header>
  <id_info>
    <org_study_id>5106</org_study_id>
    <nct_id>NCT05160311</nct_id>
  </id_info>
  <brief_title>Percutaneous Revascularization in Infarction With Late Presentation and Absence of Viability: Effects on Left Ventricular Remodeling and Contractility</brief_title>
  <official_title>Percutaneous Revascularization in Infarction With Late Presentation and Absence of Viability: Effects on Left Ventricular Remodeling and Contractility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Dante Pazzanese de Cardiologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Dante Pazzanese de Cardiologia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether late recanalization in patients with ST&#xD;
      elevation myocardial infarction (STEMI) without Viability on Cardiovascular Magnetic&#xD;
      Resonance Image (MRI) can reduce the reverse remodeling through the reduction of the End&#xD;
      Systolic Volume (ESV) at 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate whether late recanalization in patients with ST&#xD;
      elevation myocardial infarction (STEMI) without Viability on Cardiovascular Magnetic&#xD;
      Resonance can reduce the reverse remodeling through the reduction of the End Systolic Volume&#xD;
      (ESV) at 6 months and through the improvement in segmental contractility of infarcted related&#xD;
      artery at MRI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients who had underestimated STEMI with more than 24 hours up to 28 days referred by the Cross System (Central For Regulation of Health Services Supply) and the Campo Limpo Hospital (Co-participant Center) will be admitted sequentially for coronary angiography in the hemodynamics sector of the Instituto Dante Pazzanese de Cardiologia (IDPC) from August 2021 to February 2023.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate reverse myocardial remodeling after late recanalization in patients without viability</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate reverse remodeling after late recanalization in patients without viability, by the change in the End Systolic Volume (ESV) by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess change in Cardiac Ejection Fraction (EF)</measure>
    <time_frame>6 months</time_frame>
    <description>Assessement of EF by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate changes in segmental myocardial contratility</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the change of reverse VE remodeling after late recanalization by the change in myocardial segmental contratility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Assess quality of life throught WHOQOL-BREF questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute MI</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of Acute Myocardial Infarct</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Unplanned revascularization</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of Unplanned Myocardial revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cardiovascular Death</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of Cardiovascular Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of New Cardiovascular related Hospitalization</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of New Cardiovascular related Hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Stroke</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of Stroke</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <condition>Myocardial Dysfunction</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Optimized Medical Treatment (OMT)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patient considered non-viable by MRI and randomized to Optimized Medical Treatment (OMT) will be treated according to Optimized Medical Treatment guidelines for CAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angioplasty (PCI) and Optimized Medical Treatment (OMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient considered non-viable and randomized to Angioplasty will be treated with drug-eluting stent (PCI) and Optimized Medical Treatment (OMT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimized Medical Treatment (OMT)</intervention_name>
    <description>Optimized Medical Drug Treatment</description>
    <arm_group_label>Angioplasty (PCI) and Optimized Medical Treatment (OMT)</arm_group_label>
    <arm_group_label>Optimized Medical Treatment (OMT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug Eluting Stent (DES) Coronary Angioplasty</intervention_name>
    <description>Percutaneous Angioplasty with DES</description>
    <arm_group_label>Angioplasty (PCI) and Optimized Medical Treatment (OMT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. STEMI not reperfused between 24 hours and 28 days&#xD;
&#xD;
          2. MI-related artery with &gt; or = 50%&#xD;
&#xD;
          3. Segmental dysfunction in the artery related to infarction.&#xD;
&#xD;
          4. Technical feasibility for PCI recanalization&#xD;
&#xD;
          5. Absence of Myocardial Viability&#xD;
&#xD;
        3.3 Exclusion criteria&#xD;
&#xD;
          1. Age &gt; 80 years&#xD;
&#xD;
          2. &lt; 1 year life expectancy&#xD;
&#xD;
          3. Post MI Angina&#xD;
&#xD;
          4. Clinical Instability&#xD;
&#xD;
          5. Electrical Instability&#xD;
&#xD;
          6. Previous Infarction with segment disfunction&#xD;
&#xD;
          7. NYHA class III or IV heart failure.&#xD;
&#xD;
          8. Previous diagnosis of congestive heart failure or cardiomyopathy&#xD;
&#xD;
          9. Severe heart valve disease&#xD;
&#xD;
         10. Absence of segmental dysfunction in the artery related to infarction&#xD;
&#xD;
         11. Coronary angiography without obstructive lesions&#xD;
&#xD;
         12. Indication of myocardial revascularization surgery&#xD;
&#xD;
         13. Opted for clinical treatment for technical reasons&#xD;
&#xD;
         14. Serum creatinine concentration greater than 2.5 mg/dl&#xD;
&#xD;
         15. Pacemaker or Implantable Cardiodefibrillator (ICD)&#xD;
&#xD;
         16. Brain Clip Carriers&#xD;
&#xD;
         17. Patients with Cochlear Implants&#xD;
&#xD;
         18. Refusal to sign the Informed Consent Form (ICF).&#xD;
&#xD;
         19. Inability to maintain outpatient follow-up for 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Valente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Dante Pazzanese de Cardiologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Valente, MD</last_name>
    <phone>5585988083444</phone>
    <email>barbaravalente@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pedro Farsky, MD, PhD</last_name>
    <phone>5511991662309</phone>
    <email>pedro.farsky@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04012909</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BARBARA VALENTE, MD</last_name>
      <phone>551150856204</phone>
      <email>BARBARAVALENTE@HOTMAIL.COM</email>
    </contact>
    <contact_backup>
      <last_name>RENATA VIANA, MD</last_name>
      <phone>551150856204</phone>
      <email>RVIANA@DANTEPAZZANESE.ORG.BR</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI). Lancet. 1987 Oct 17;2(8564):871-4.</citation>
    <PMID>2889079</PMID>
  </reference>
  <reference>
    <citation>O'Neill W, Timmis GC, Bourdillon PD, Lai P, Ganghadarhan V, Walton J Jr, Ramos R, Laufer N, Gordon S, Schork MA, et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med. 1986 Mar 27;314(13):812-8.</citation>
    <PMID>2936956</PMID>
  </reference>
  <reference>
    <citation>Piegas LS, Feitosa G, Mattos LA, Nicolau JC, Rossi Neto JM et al. Brazilian Society of Cardiology. IV Guideline of the Brazilian Society of Cardiology on The Treatment of Acute Myocardial Infarction with ST Segment Supradeslevel. Arq Bras Cardiol.2009;93(6 supl.2):e179-e264.</citation>
  </reference>
  <reference>
    <citation>Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393.</citation>
    <PMID>28886621</PMID>
  </reference>
  <reference>
    <citation>Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, López-Sendón J; GRACE Investigators. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet. 2002 Feb 2;359(9304):373-7.</citation>
    <PMID>11844506</PMID>
  </reference>
  <reference>
    <citation>Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, Krzeminska-Pakula M, Santopinto J, Hecquet C, Vittori L; TETAMI Investigators. Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial. Circulation. 2003 Oct 21;108(16 Suppl 1):III14-21.</citation>
    <PMID>14605015</PMID>
  </reference>
  <reference>
    <citation>Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet. 1993 Sep 25;342(8874):759-66.</citation>
    <PMID>8103874</PMID>
  </reference>
  <reference>
    <citation>Dzavik V, Beanlands DS, Davies RF, Leddy D, Marquis JF, Teo KK, Ruddy TD, Burton JR, Humen DP. Effects of late percutaneous transluminal coronary angioplasty of an occluded infarct-related coronary artery on left ventricular function in patients with a recent (&lt; 6 weeks) Q-wave acute myocardial infarction (Total Occlusion Post-Myocardial Infarction Intervention Study [TOMIIS]--a pilot study). Am J Cardiol. 1994 May 1;73(12):856-61.</citation>
    <PMID>8184807</PMID>
  </reference>
  <reference>
    <citation>Yousef ZR, Marber MS. The open artery hypothesis: potential mechanisms of action. Prog Cardiovasc Dis. 2000 May-Jun;42(6):419-38. Review.</citation>
    <PMID>10871164</PMID>
  </reference>
  <reference>
    <citation>Horie H, Takahashi M, Minai K, Izumi M, Takaoka A, Nozawa M, Yokohama H, Fujita T, Sakamoto T, Kito O, Okamura H, Kinoshita M. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Circulation. 1998 Dec 1;98(22):2377-82.</citation>
    <PMID>9832481</PMID>
  </reference>
  <reference>
    <citation>Yousef ZR, Redwood SR, Bucknall CA, Sulke AN, Marber MS. Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of the Open Artery Trial (TOAT Study). J Am Coll Cardiol. 2002 Sep 4;40(5):869-76.</citation>
    <PMID>12225709</PMID>
  </reference>
  <reference>
    <citation>Silva JC, Rochitte CE, Júnior JS, Tsutsui J, Andrade J, Martinez EE, Moffa PJ, Menegheti JC, Kalil-Filho R, Ramires JF, Nicolau JC. Late coronary artery recanalization effects on left ventricular remodelling and contractility by magnetic resonance imaging. Eur Heart J. 2005 Jan;26(1):36-43. Epub 2004 Nov 29.</citation>
    <PMID>15615797</PMID>
  </reference>
  <reference>
    <citation>Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Forman S, Ruzyllo W, Maggioni AP, White H, Sadowski Z, Carvalho AC, Rankin JM, Renkin JP, Steg PG, Mascette AM, Sopko G, Pfisterer ME, Leor J, Fridrich V, Mark DB, Knatterud GL; Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006 Dec 7;355(23):2395-407. Epub 2006 Nov 14.</citation>
    <PMID>17105759</PMID>
  </reference>
  <reference>
    <citation>Abbate A, Biondi-Zoccai GG, Appleton DL, Erne P, Schoenenberger AW, Lipinski MJ, Agostoni P, Sheiban I, Vetrovec GW. Survival and cardiac remodeling benefits in patients undergoing late percutaneous coronary intervention of the infarct-related artery: evidence from a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2008 Mar 4;51(9):956-64. doi: 10.1016/j.jacc.2007.11.062. Epub 2008 Feb 6.</citation>
    <PMID>18308165</PMID>
  </reference>
  <reference>
    <citation>Sabaté M. Revascularization of the infarct-related artery: never too late to do well. J Am Coll Cardiol. 2008 Mar 4;51(9):965-7. doi: 10.1016/j.jacc.2008.01.003. Epub 2008 Feb 5.</citation>
    <PMID>18308166</PMID>
  </reference>
  <reference>
    <citation>Erne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT, Dubach P, Resink TJ, Pfisterer M. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA. 2007 May 9;297(18):1985-91.</citation>
    <PMID>17488963</PMID>
  </reference>
  <reference>
    <citation>Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002 Apr 3;39(7):1151-8.</citation>
    <PMID>11923039</PMID>
  </reference>
  <reference>
    <citation>Udelson JE, Pearte CA, Kimmelstiel CD, Kruk M, Kufera JA, Forman SA, Teresinska A, Bychowiec B, Marin-Neto JA, Höchtl T, Cohen EA, Caramori P, Busz-Papiez B, Adlbrecht C, Sadowski ZP, Ruzyllo W, Kinan DJ, Lamas GA, Hochman JS. The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone. Am Heart J. 2011 Mar;161(3):611-21. doi: 10.1016/j.ahj.2010.11.020.</citation>
    <PMID>21392619</PMID>
  </reference>
  <reference>
    <citation>Bellenger NG, Yousef Z, Rajappan K, Marber MS, Pennell DJ. Infarct zone viability influences ventricular remodelling after late recanalisation of an occluded infarct related artery. Heart. 2005 Apr;91(4):478-83.</citation>
    <PMID>15772205</PMID>
  </reference>
  <reference>
    <citation>Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000 Nov 16;343(20):1445-53.</citation>
    <PMID>11078769</PMID>
  </reference>
  <reference>
    <citation>Selvanayagam JB, Kardos A, Francis JM, Wiesmann F, Petersen SE, Taggart DP, Neubauer S. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation. 2004 Sep 21;110(12):1535-41. Epub 2004 Sep 7.</citation>
    <PMID>15353496</PMID>
  </reference>
  <reference>
    <citation>Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation. 2008 Jan 1;117(1):103-14. doi: 10.1161/CIRCULATIONAHA.107.702993. Review.</citation>
    <PMID>18172050</PMID>
  </reference>
  <reference>
    <citation>Romero J, Xue X, Gonzalez W, Garcia MJ. CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease: a meta-analysis of prospective trials. JACC Cardiovasc Imaging. 2012 May;5(5):494-508. doi: 10.1016/j.jcmg.2012.02.009. Review.</citation>
    <PMID>22595157</PMID>
  </reference>
  <reference>
    <citation>Gerber BL, Rousseau MF, Ahn SA, le Polain de Waroux JB, Pouleur AC, Phlips T, Vancraeynest D, Pasquet A, Vanoverschelde JL. Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy. J Am Coll Cardiol. 2012 Feb 28;59(9):825-35. doi: 10.1016/j.jacc.2011.09.073.</citation>
    <PMID>22361403</PMID>
  </reference>
  <reference>
    <citation>STATACorp. 2019. Stata Statistical Software: Release 16.0. College Station, Texas : Stata Corporation</citation>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Dante Pazzanese de Cardiologia</investigator_affiliation>
    <investigator_full_name>Barbara Porto Valente</investigator_full_name>
    <investigator_title>Cardiology Physician</investigator_title>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>myocardial viability</keyword>
  <keyword>Late percutaneous coronary intervention</keyword>
  <keyword>myocardial remodelling</keyword>
  <keyword>Myocardial reperfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

